3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting. (March 2019) - Pivot, X.; Bondarenko, I.; Dvorkin, M.; Sarosiek, T.; Wojtukiewicz, M.; Shparyk, Y.; Kim, Y.; Lim, J.